Acacia Pharma Agrees To Be Bought By Eagle Pharma In €94.7 Mln Cash, Stock Deal

Acacia Pharma Group Plc (ACPH.BR) announced Monday its agreement to be acquired by Eagle Pharmaceuticals, Inc. (EGRX) by way of a scheme of arrangement in around 94.7 million euros cash and stock deal.

The total consideration equates to 0.90 euro for each Scheme Share. Under the terms of the proposed scheme of arrangement, each Scheme Shareholder will receive 0.68 euro in cash and 0.0049 New Eagle Shares. The cash portion of the deal represents approximately 75 percent of the total price, and the shares represent the remaining 25 percent.

The Acacia Directors consider the proposed transaction to be the best available option for Acacia Shareholders and intend unanimously to recommend that shareholders vote in favour of the Scheme.

Eagle has received irrevocable undertakings representing approximately 48.78 percent of the issued share capital of Acacia.

The Scheme is expected to become effective between the middle of May 2022 and 30 June 2022, subject to the satisfaction of the terms.

The agreement follows a comprehensive review and assessment of all strategic alternatives, including consideration of options to raise additional capital.

Acacia noted that it met its formulary goals for both Barhemsys and Byfavo in fiscal 2021 and sees significant future commercial potential for the products.

However, the company's standalone financial condition has been negatively impacted by physical access limitations caused by the global COVID-19 pandemic, and a significant latency of demand due to postponement of surgical procedures.

Accordingly, Acacia expects it would require a minimum of around $115 million of additional cash to fund operations to break-even, based on projections assuming break-even by early fiscal 2025.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT